Bristol – 21st April 2020
Unai, the Bristol based data science and software company, today announced it has appointed Mark Ellis as Interim Chief Commercial Officer in order to support its rapid expansion in healthcare and life sciences fields.
Mark, who joined the Unai Board as a Non-Executive in December 2019, brings with him extensive experience of working with rapidly scaling software organisations serving the healthcare sector, particularly in data-rich fields such as genomics and pathology. He has held senior positions in global businesses including Liquent (Thomson Reuters) and worked with leading venture capital and private equity houses. Mark’s focus is in helping companies to realise their growth potential, by establishing strong customer and partner relationships.
Speaking of the appointment, Mark said: “Having witnessed Unai’s growth and the strength of their team as a board member, I was delighted to accept an interim position. The pathology and genomics fields within the public and private sectors are under enormous pressures to do more, with fewer resources. The Unai team is proven to be able to bring interoperability across disparate software systems, at scale and pace. It is fantastic to be taking this post as they have enormous potential, especially as a leading software partner in the roll out of genomic medicine across the UK and beyond.
James Baldwin, Unai’s CEO added: “Mark’s track record speaks for itself and he will play a pivotal role in the growth of the company. We have a range of deep sector experts on our team, from data scientists, software engineers, research and clinical genomics experts. Now with Mark leading our commercial team, I am excited to see our expansion plans unfold.”
For more information please contact Lucy Cox at press@unai.com or visit unai.com
A full press kit including photos and plaintext files can be found here